New questions are being raised about the clinical trial of a widely used heart drug, and critics are calling for an independent investigation, after a medical device used during the study was later ...

RARITAN, NJ, Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved XARELTO® to reduce the risk of stroke and systemic embolism in patients with ...

The GALILEO trial has been halted after an early peek at the data showed that rivaroxaban (Xarelto; Bayer/Janssen) was associated with greater risks of all-cause mortality, thromboembolic events, and ...

Rivaroxaban(Xarelto, Janssen) received FDA approval today for the prevention of deep vein thrombosis which may lead to a pulmonary embolism in patients undergoing knee or hip replacement surgery. The ...

Treatment with rivaroxaban plus aspirin significantly reduced the risk of major adverse limb and cardiovascular events in the VOYAGER PAD study. A supplemental New Drug Application (sNDA) for ...

PHILADELPHIA -- Patients were harmed when given rivaroxaban (Xarelto) to prevent valve surface thromboembolism after transcatheter aortic valve replacement (TAVR) if they had no established indication ...

The FDA approved the first generics of the direct oral anticoagulant rivaroxaban, the agency announced on Tuesday. Rivaroxaban 2.5 mg tablets from Lupin and Taro are now considered therapeutic ...

Please provide your email address to receive an email when new articles are posted on . The prospective, multinational, investigator-initiated, single-arm, phase 4 HoT-PE trial included adults with ...

Please provide your email address to receive an email when new articles are posted on . In a cohort of patients with renal impairment who underwent peripheral revascularization, rivaroxaban reduced ...

It’s time to do an update on the treatment of atrial fibrillation. It’s been a while, and there are worthy things to report from the real world. Always start with basics: The most important aspect of ...

The ROCKET AF (Stroke Prevention Using the Oral Direct Factor Xa Inhibitor Rivaroxaban Compared With Warfarin in Patients with Nonvalvular Atrial Fibrillation) trial tested rivaroxaban (20 mg/day) ...